A Phase 1 interventional study of Baricitinib and Digoxin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the effect of baricitinib on the levels of digoxin in the blood stream and how long it takes the body to remove digoxin. This study will also look at how safe and well-tolerated baricitinib is when given at the same time as digoxin in healthy participants. This study will last approximately 3-4 weeks.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Digoxin - 0.5 milligrams (mg) administered orally, twice daily (BID), 12 hours apart on Day 1. Then, 0.25 mg administered orally, once daily (QD) on Days 2 through 16. Baricitinib - 10 mg administered orally, QD, on Days 8 through 16.
Drug: Baricitinib · Drug: Digoxin
Administered orally
Also known as: LY3009104
Administered orally
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin
Time frame: Predose up to 24 hours post-dose on Days 7 and 16
PK: Maximum Concentration (Cmax) of Digoxin
Time frame: Predose up to 24 hours post-dose on Days 7 and 16
PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin
Time frame: Predose up to 24 hours post-dose on Days 7 and 16
PK: Amount of Drug Excreted Unchanged During 1 Dosing Interval (Aeτ) of Digoxin
Time frame: 0 to 24 hours post-dose on Days 7 and 16
PK: Renal Clearance (CLr) of Digoxin
CLr is the volume of plasma from which study drug is completely removed by the kidney in a given time and is calculated as Aeτ divided by AUCτ.
Time frame: Predose to 24 hours post-dose on Days 7 and 16
| Milestone | Baricitinib + Digoxin |
|---|---|
| Started | 28 |
| Completed | 28 |
| Not completed | 0 |
| nanograms*hour/milliliter (ng*h/mL) | Digoxin Only | Baricitinib + Digoxin |
|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval (AUCτ) of Digoxin | 18.7 ± 18 | 16.8 ± 20 |
| nanograms/milliliter (ng/mL) | Digoxin Only | Baricitinib + Digoxin |
|---|---|---|
| PK: Maximum Concentration (Cmax) of Digoxin | 2.04 ± 23 | 1.80 ± 20 |
| hours (h) | Digoxin Only | Baricitinib + Digoxin |
|---|---|---|
| PK: Time of Maximum Observed Drug Concentration (Tmax) of Digoxin | 1.00 (0.50 to 2.00) | 1.00 (0.42 to 2.00) |
| milligrams (mg) | Digoxin Only | Baricitinib + Digoxin |
|---|---|---|
| PK: Amount of Drug Excreted Unchanged During 1 Dosing Interval (Aeτ) of Digoxin | 0.177 ± 18 | 0.155 ± 22 |
CLr is the volume of plasma from which study drug is completely removed by the kidney in a given time and is calculated as Aeτ divided by AUCτ.
| Liters/hour (L/h) | Digoxin Only | Baricitinib + Digoxin |
|---|---|---|
| PK: Renal Clearance (CLr) of Digoxin | 9.46 ± 20 | 9.20 ± 18 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Digoxin Only | — | 0/28 (0%) | 10/28 (35.7%) |
| Baricitinib + Digoxin | — | 0/28 (0%) | 6/28 (21.4%) |
| Event | Digoxin Only | Baricitinib + Digoxin |
|---|---|---|
| HeadacheNervous system disorders | 5/28 | 2/28 |
| DiarrhoeaGastrointestinal disorders | 1/28 | 3/28 |
| PollakiuriaRenal and urinary disorders | 3/28 | 0/28 |
| FatigueGeneral disorders | 2/28 | 1/28 |
All enrolled participants.
| Age, Continuous(years) | Baricitinib + Digoxin |
|---|---|
| Mean | 33.4 ± 11.3 |
| Sex: Female, Male(Participants) | Baricitinib + Digoxin |
|---|---|
| Female | 0 |
| Male | 28 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib + Digoxin |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 28 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Baricitinib + Digoxin |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 24 |
| More than one race | 3 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Baricitinib + Digoxin |
|---|---|
| United Kingdom | 28 |
The record gives a start of May 2013, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib